Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of adding fractionated Mylotarg to daunorubicin and cytarabine in adults aged 50-70 years with acute myeloid leukemia
2007-002933-36Phase 3Completed
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Aug 2007
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (2 arms), sponsored by Centre Hospitalier de Versailles. Primary endpoint: Event-free survival. Started Aug 2007; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2007-002933-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002933-36.